According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 9.93956. At the end of 2023 the company had a P/S ratio of 13.1.
Year | P/S ratio | Change |
---|---|---|
2023 | 13.1 | -53.38% |
2022 | 28.2 | 17.32% |
2021 | 24.0 | -21.59% |
2020 | 30.6 | -47.89% |
2019 | 58.8 | -40.29% |
2018 | 98.5 | -29.73% |
2017 | 140 | 105.69% |
2016 | 68.1 | -65.05% |
2015 | 195 | 31.6% |
2014 | 148 | 70.45% |
2013 | 86.9 | 505.26% |
2012 | 14.4 | 241.19% |
2011 | 4.21 | 0.83% |
2010 | 4.17 | -43.09% |
2009 | 7.33 | -31.15% |
2008 | 10.7 | -54.28% |
2007 | 23.3 | -20.88% |
2006 | 29.4 | -34.68% |
2005 | 45.1 | 33.85% |
2004 | 33.7 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Novartis NVS | 3.96 | -60.14% | ๐จ๐ญ Switzerland |
Sanofi SNY | 2.45 | -75.38% | ๐ซ๐ท France |
Regeneron Pharmaceuticals REGN | 7.59 | -23.68% | ๐บ๐ธ USA |
Sarepta Therapeutics
SRPT | 9.62 | -3.25% | ๐บ๐ธ USA |
Regulus Therapeutics RGLS | N/A | N/A | ๐บ๐ธ USA |
OPKO Health
OPK | 0.9848 | -90.09% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | 0.9471 | -90.47% | ๐ฎ๐ฑ Israel |
Arrowhead Pharmaceuticals
ARWR | 14.9 | 50.00% | ๐บ๐ธ USA |